Background
==========

Within the last decade, the concept of healthcare-associated (HCA) infection has been introduced, and HCA infection has been described as an epidemiological category different from both community-acquired (CA) and nosocomial infection \[[@B1],[@B2]\]. Most importantly, mortality in HCA infection seems to be generally higher than that in CA infection, and similar to that in nosocomial infection \[[@B2]-[@B4]\]. However, there are conflicting results regarding whether HCA infection is an independent risk factor for mortality in bloodstream infection \[[@B1],[@B5]\]. A few pathogens have been studied in terms of HCA infection with *S. aureus* dominating the research, and these studies reported inconsistent data concerning the impact of HCA infection on mortality \[[@B6]-[@B13]\]. For gram-negative bacteria, the data on the impact of HCA infection on mortality were conflicting, as well \[[@B9]-[@B12]\].

*Klebsiella pneumoniae* is one of the most important gram-negative bacteria clinically, and *K. pneumoniae* bloodstream infection (*Kp*BSI) has a mortality rate of about 20% \[[@B11],[@B14]-[@B16]\]. Classically, *Kp*BSI was simply classified into CA and nosocomial infections depending on bacteremia onset time: within 48 hours and after 48 hours of admission, respectively, and the different characteristics of CA-*Kp*BSI versus nosocomial *Kp*BSI have been well evaluated \[[@B11],[@B14],[@B15],[@B17],[@B18]\]. CA-*Kp*BSI is usually associated with liver abscesses in patients with diabetes in East Asian countries, such as Korea and Taiwan \[[@B19]-[@B22]\]. On the other hand, nosocomial *Kp*BSI presents as primary bacteremia and/or pneumonia in patients with severe underlying diseases like malignancies. Thus, nosocomial infection has a higher mortality than CA infection \[[@B11],[@B14],[@B15],[@B17],[@B18]\]. However, there have been few studies of HCA-*Kp*BSI \[[@B11]-[@B13]\]. Therefore, we aimed to evaluate the impact of HCA infection on mortality and to compare the clinical characteristics of HCA and CA infection in patients with community-onset *Kp*BSI.

Methods
=======

Study setting and patients
--------------------------

We conducted a retrospective study of the medical records of the patients with *Kp*BSI from January 2003 to December 2008 at Seoul National University Hospital (a 1,600-bed tertiary-care hospital, Seoul, Korea) and Seoul National University Bundang Hospital (a 900-bed tertiary-care hospital, Seongnam, Korea). All adult patients (≥18 year) who had *Kp*BSI within 48 hours of admission were enrolled. When there were multiple *Kp*BSI episodes only the first was included. We collected patient's data on age, sex, underlying disease, site of infection, laboratory findings, microbiologic characteristics and treatment outcomes. To assess treatment outcomes we investigated 30-day mortality. This study was approved by the institutional review board of Seoul National University Hospital (IRB No. H-1010-062-336) and Seoul National University Bundang Hospital (IRB No. B-0910/086-004) according to the Helsinki Declaration.

Definitions
-----------

Community-onset *Kp*BSI was defined as *Kp*BSI occurring within 48 hours of admission. HCA-*Kp*BSI was defined when a patient had one of the following medical histories: (1) intravenous therapy at home or in an outpatient clinic within the previous 30 days; (2) renal dialysis in a hospital or clinic within the previous 30 days; (3) hospitalization for 2 or more days within the previous 90 days; (4) residence in a nursing home or long-term care facility for 2 or more days \[[@B1]\]. Patients without any of these factors were classified as CA-*Kp*BSI.

Biliary tract disease was defined when one or more complicated biliary stone was present, or there was a structural biliary abnormality due to benign or malignant disease. Chronic liver disease referred to chronic hepatitis and liver cirrhosis due to any cause. Charlson's weighted index of co-morbidity and the Pitt bacteremia score were used to evaluate the severities of underlying disease and of acute illness, respectively \[[@B23],[@B24]\]. Shock was defined as a decrease in systolic blood pressure to 90mmHg or less, or a decrease of at least 40mmHg below baseline blood pressure despite adequate fluid resuscitation \[[@B25]\]. An absolute neutrophil count of less than 500/mL was defined as neutropenia. Polymicrobial infection was defined when any pathogen other than *K. pneumoniae* was isolated from blood culture at the same time as the *K. pneumoniae*, and the isolated pathogen also had clinical significance. Infection focus was assessed clinically by attending physician in accordance with site of isolation of *K. pneumoniae.*

The empirical antimicrobial therapy was defined as the initial antibiotic choice before the results of blood culture and antimicrobial susceptibility tests were available, and the definitive antimicrobial therapy was defined as the antibiotic choice after the report of microbiologic tests. *K. pneumoniae* which was not susceptible to either cefotaxime or ceftazidime was considered as 'suspected extended-spectrum beta-lactamase (ESBL) producing *K. pneumoniae*'. Antimicrobial therapy was considered as 'inappropriate' when the treatment regimen did not include any antibiotic active *in vitro*. In addition 3^rd^ generation cephalosporin monotherapy for 'suspected ESBL-producing *K. pneumoniae*' was considered 'inappropriate', regardless of the results of antibiotic susceptibility tests.

Microbiological analysis
------------------------

All isolates were defined by BacT/ALERT FA and FN (bioMe´rieux, Durham, North Carolina). Antimicrobial susceptibility was identified by disk diffusion tests from 2003 to 2006, and by Microscan WalkAway-96 (Siemens Healthcare Diagnostics, Deerfield, Illinois) from 2007 to 2008, using the criteria of the Clinical and Laboratory Standards Institute (CLSI; formerly, National Committee for Clinical Laboratory Standards) guidelines. For the available 'suspected ESBL-producing *K. pneumoniae*' isolates, ESBL production was determined by the double disk synergy test according to the CLSI performance standards \[[@B26]\].

Statistical analysis
--------------------

Student's *t*-test was used to compare continuous variables and the χ^2^ test or Fisher's exact test was used to compare categorical variables. To identify independent risk factors for 30-day mortality, a stepwise logistic regression model was used. Risk factors with a *p* value \<0.10 in the univariate analysis for 30-day mortality were included in the initial model, and forward stepwise selection was performed to develop the final model. We included the Pitt bacteremia score instead of shock and, the Charlson's weighted index of co-morbidity instead of underlying diseases to avoid data overlap in the multivariate analysis. *p* \<0.05 was considered statistically significant. PASW for Windows (version 18 software package; SPSS Inc., Chicago, IL, USA) was used for all analyses.

Results
=======

Demographics and underlying diseases
------------------------------------

592 patients with community-onset *Kp*BSI were identified in the 6-year period. Of these, 553 (93%) were analyzed, because 34 patients were lost to follow-up and medical record was not available in 5 patients. Of the 553 patients with community-onset *Kp*BSI, 313 (57%) were classified as HCA-*Kp*BSI and 240 (43%) as CA-*Kp*BSI. The mean age of the 553 patients was 61 years (median: 63 years, range: 18--103), and 348 (63%) of the patients were male. Solid tumor was the most common underlying disease (238 patients, 43%). 145 (26%) patients had diabetes mellitus and 123 (22%) had chronic liver disease.

The demographics and underlying diseases of HCA-*Kp*BSI and CA-*Kp*BSI are listed in Table [1](#T1){ref-type="table"}. Solid tumor (58% vs*.* 24%; *p* \<0.001), hematologic malignancy (7% vs*.* 2%; *p* = 0.002) and chronic liver disease (27% vs*.* 16%; *p =* 0.003) were more common in HCA-*Kp*BSI than in CA-*Kp*BSI. Diabetes mellitus (31% vs*.* 23%; *p =* 0.031) was more common in CA-*Kp*BSI than in HCA-*Kp*BSI.

###### 

**Clinical characteristics of community-acquired and healthcare-associated infections in patients with community-onset*Klebsiella pneumoniae*bloodstream infection**

                                                       **CA-*Kp*BSI**   **HCA-*Kp*BSI**   ***p***
  --------------------------------------------------- ---------------- ----------------- ---------
  Age (years) (mean ±SD)                                63.0 (±13.6)     60.3 (±12.9)      0.015
  Male sex                                               142 (59.2)       206 (65.8)       0.124
  Underlying disease                                                                     
    Diabetes mellitus                                    74 (30.8)         71 (22.7)       0.031
    Chronic liver disease                                39 (16.3)         84 (26.8)       0.003
    Biliary tract disease                                42 (17.5)         43 (13.7)       0.224
    Chronic kidney disease                                13 (5.4)         19 (6.1)        0.774
    Respiratory disease                                   18 (7.5)         21 (6.7)        0.719
    Solid tumor                                          58 (24.2)        180 (57.5)      \<0.001
    Hematologic malignancy                                4 (1.7)          23 (7.3)        0.002
    Solid organ transplantation                           5 (2.1)           9 (2.9)        0.557
  Charlson's WIC (≥3)                                    47 (19.6)        141 (45.0)      \<0.001
  Primary infection site                                                                 
    Urinary tract                                        31 (12.9)         34 (10.9)       0.457
    Peritoneum                                            11 (4.6)         46 (14.7)      \<0.001
    Pancreatobiliary tract                               82 (34.2)        102 (32.6)       0.696
    Liver                                                67 (27.9)         41 (13.1)      \<0.001
    Lung                                                  16 (6.7)         28 (8.9)        0.326
    Skin and soft tissue                                  4 (1.7)           8 (2.6)        0.477
    Bone                                                  4 (1.7)           2 (0.6)        0.411
    Central nervous system                                1 (0.4)            0 (0)         0.434
    Others^a^                                             1 (0.4)           3 (1.0)        0.637
    Unknown                                               21 (8.8)         52 (16.6)       0.007
  Metastatic infection                                    11 (4.6)          9 (2.9)        0.286
  Endophthalmitis                                         5 (2.1)           3 (1.0)        0.303
  Pitt bacteremia score (≥4)                             36 (15.0)         56 (17.9)       0.366
  Shock at presentation                                  55 (22.9)        101 (32.3)       0.015
  Neutropenia at presentation                             3 (1.3)          42 (13.4)      \<0.001
  Polymicrobial infection                                34 (14.2)         47 (15.0)       0.780
  Initial antimicrobial regimen                                                          
    Piperacillin-tazobactam                               9 (3.8)          30 (9.6)        0.008
    Quinolone                                             23 (9.6)         18 (5.8)        0.088
    1^st^ generation cephalosporin                        2 (0.8)            0 (0)         0.188
    3^rd^ generation cephalosporin                       173 (72.1)       186 (59.4)       0.002
    Carbapenem                                           30 (12.5)         48 (15.3)       0.342
  Inappropriate empirical antimicrobial therapy           14 (5.8)         26 (8.3)        0.266
  Inappropriate definitive antimicrobial therapy^b^     7/223 (3.1)       7/278 (2.5)      0.675
  30-day mortality                                       27 (11.3)         70 (22.4)       0.001

Data indicate no. (%) of patients. WIC, weighted index of co-morbidity; CA-*Kp*BSI, community-acquired *Klebsiella pneumoniae* bloodstream infection; HCA-*Kp*BSI, healthcare-associated *Klebsiella pneumoniae* bloodstream infection. ^a^ Others were one appendicitis, one pericarditis and two periodontitis. ^b^ 52 patients were excluded from the analysis (15 patients were transferred to other hospitals and 37 died before the culture results were available).

Primary sites of infection and treatment outcomes
-------------------------------------------------

The pancreatobiliary tract was the most common site of infection (184 cases, 33%). Liver (108, 20%) and primary bacteremia (unknown focus) (73, 13%) were also frequent sites of infection. Initially 156 (28%) patients presented shock and 45 (8%) had neutropenia. 40 (7%) patients of the 553 patients were treated with inappropriate empirical antimicrobial therapy. After excluding 52 of the 553 patients (15 were transferred to other hospitals and 37 died before the culture results were reported), 14 of the remaining 501 patients (3%) were found to have been treated with inappropriate definitive antimicrobial therapy.

The primary sites of infection and treatment outcomes of HCA-*Kp*BSI and CA-*Kp*BSI are also compared in Table [1](#T1){ref-type="table"}. Peritonitis (15% vs*.* 5%; *p* \<0.001) and primary bacteremia (17% vs*.* 9%; *p =* 0.007) were more common in HCA-*Kp*BSI than in CA-*Kp*BSI. On the other hand, liver abscess (28% vs*.* 13%; *p* \<0.001) was more frequent in CA-*Kp*BSI than in HCA-*Kp*BSI. Initial shock (32% vs*.* 23%; *p =* 0.015) and neutropenia (13% vs*.* 1%; *p* \<0.001) were more common in HCA-*Kp*BSI than in CA-*Kp*BSI. The 30-day mortality of HCA-*Kp*BSI was higher than that of CA-*Kp*BSI (22% vs*.* 11%; *p =* 0.001).

Antimicrobial susceptibility
----------------------------

48 of the 553 isolates (9%) were not susceptible to ciprofloxacin and 37 isolates (7%) were not susceptible to either cefotaxime or ceftazidime. Of these 37 isolates, 27 were available for ESBL confirmatory tests and we performed the double disk synergy test on them. Eighteen were confirmed as producing ESBL. The antimicrobial susceptibilities of HCA-*Kp*BSI and CA-*Kp*BSI are compared in Table [2](#T2){ref-type="table"}. A significantly higher proportion of the HCA-*Kp*BSI than of the CA-*Kp*BSI was resistant to tested antimicrobial agents other than imipenem and amikacin.

###### 

**Comparison of the antimicrobial susceptibility of community-acquired (CA) and healthcare-associated (HCA)*Klebsiella pneumoniae*bloodstream infection (*Kp*BSI)**

  **Antibiotics**                    **CA-*Kp*BSI (n = 240)**   **HCA-*Kp*BSI (n = 313)**   ***p***
  --------------------------------- -------------------------- --------------------------- ---------
  Ciprofloxacin                            12/240 (5.0)               36/313 (11.5)          0.007
  Extended-spectrum cephalosporin          8/240 (3.3)                29/313 (9.3)           0.006
    Cefotaxime                             8/240 (3.3)                25/313 (8.0)           0.022
    Ceftazidime                            6/240 (2.5)                25/313 (8.0)           0.005
  ESBL-production^a^                       2/237 (0.8)                16/310 (5.2)           0.006
  Piperacillin plus tazobactam             6/239 (2.5)                19/311 (6.1)           0.045
  Aztreonam                                5/175 (2.9)                26/253 (11.1)          0.004
  Imipenem                                 1/240 (0.4)                 1/313 (0.3)           1.000
  Amikacin                                 7/240 (2.9)                17/313 (5.4)           0.150
  Gentamicin                               6/240 (2.5)                22/313 (7.0)           0.016
  Tobramycin                               7/177 (4.0)                26/253 (10.3)          0.015

Data indicate number of non-susceptible isolates/total number of tested isolates (%).

T, total number of tested isolates; ESBL, extended-spectrum beta-lactamase.

^a^ 5 isolates among the CA-*Kp*BSI were available for ESBL confirmatory tests and 14 among the HCA-*Kp*BSI.

Risk factors for 30-day mortality
---------------------------------

The results of the univariate analyses of risk factors for 30-day mortality are shown in Table [3](#T3){ref-type="table"}. High Charlson's weighted index of co-morbidity was a risk factor (odds ratio \[OR\], 2.86; 95% confidence interval \[CI\], 1.83-4.48) and, when we analyzed each underlying disease, solid tumor (OR, 3.32; 95% CI, 2.09-5.28) and hematologic malignancy (OR, 3.52; 95% CI, 1.58-7.84) also turned out to be significant risk factors. Infections of unknown origin (OR, 3.71; 95% CI, 2.17-6.34) and respiratory infections (OR, 3.38; 95% CI, 1.76-6.48) developed more frequently in non-survivors than in survivors. In contrast, liver abscess (OR, 0.11; 95% CI, 0.03-0.35) and pancreatobiliary infection (OR, 0.50; 95% CI, 0.30-0.84) were more common in survivors than in non-survivors. In addition, high Pitt bacteremia score (OR, 8.04; 95% CI, 4.87-13.28), neutropenia at initial presentation (OR, 4.48; 95% CI, 2.37-8.46), inappropriate empirical antimicrobial therapy (OR, 2.46; 95% CI, 1.22-4.96), polymicrobial infection (OR, 2.30; 95% CI, 1.34-3.94) and healthcare-associated infection (OR, 2.27; 95% CI, 1.41-3.68) were risk factors in univariate analyses. There was no significant difference in rates of antimicrobial resistance to ciprofloxacin (7.0% in survivors vs. 9.3% in non-survivors; *p* = 0.440) and extended-spectrum cephalosporin (6.4% in survivors vs. 8.2% in non-survivors; *p* = 0.499) between survivors and non-survivors.

###### 

**Risk factors for 30-day mortality among patients with community-onset*Klebsiella pneumoniae*bloodstream infection in univariate analysis**

                                                       **No. of survivors**   **No. of non-survivors**    **OR (95% CI)**    ***p***
  --------------------------------------------------- ---------------------- -------------------------- ------------------- ---------
  Age (year) (mean ±SD)                                    61.1 (±13.5)             63.3 (±12.1)                              0.146
  Male sex                                                  287 (62.9)               61 (62.9)           1.00 (0.63-1.57)     0.992
  Underlying disease                                                                                                             
    Diabetes mellitus                                       128 (28.1)               17 (17.5)           0.55 (0.31-0.96)     0.032
    Chronic liver disease                                   94 (20.6)                29 (29.9)           1.64 (1.01-2.68)     0.046
    Biliary tract disease                                   77 (16.9)                 8 (8.2)            0.44 (0.21-0.95)     0.032
    Chronic kidney disease                                   28 (6.1)                 4 (4.1)            0.66 (0.26-1.92)     0.440
    Respiratory disease                                      34 (7.5)                 5 (5.2)            0.68 (0.26-1.77)     0.421
    Solid tumor                                             173 (37.9)               65 (67.0)           3.32 (2.09-5.28)    \<0.001
    Hematologic malignancy                                   16 (3.5)                11 (11.3)           3.52 (1.58-7.84)     0.003
    Solid organ transplantation                              13 (2.9)                 1 (1.0)            0.36 (0.05-2.75)     0.482
  Charlson\'s WIC (≥3)                                      135 (29.6)               53 (54.6)           2.86 (1.83-4.48)    \<0.001
  Primary infection site                                                                                                         
    Urinary tract                                           58 (12.7)                 7 (7.2)            0.53 (0.24-1.22)     0.126
    Peritoneum                                               42 (9.2)                15 (15.5)           1.80 (0.96-3.40)     0.066
    Pancreatobiliary tract                                  163 (35.7)               21 (21.6)           0.50 (0.30-0.84)     0.007
    Liver                                                   105 (23.0)                3 (3.1)            0.11 (0.03-0.35)    \<0.001
    Lung                                                     27 (5.9)                17 (17.5)           3.38 (1.76-6.48)    \<0.001
    Skin and soft tissue                                     8 (1.8)                  4 (4.1)            2.41 (0.71-8.17)     0.239
    Bone                                                     5 (1.1)                  1 (1.0)            0.94 (0.11-8.13)     1.000
    Central nervous system                                   1 (0.2)                   0 (0)             0.82 (0.79-0.86)     1.000
    Others^a^                                                3 (0.7)                  1 (1.0)            1.57 (0.16-15.28)    0.539
    Unknown                                                  45 (9.9)                28 (28.9)           3.71 (2.17-6.34)    \<0.001
  Metastatic infection                                       18 (3.9)                 2 (2.1)            0.51 (0.12-2.25)     0.551
  Endophthalmitis                                            8 (1.8)                   0 (0)             0.82 (0.79-0.86)     0.362
  Pitt bacteremia score (≥4)                                46 (10.1)                46 (47.4)           8.04 (4.87-13.28)   \<0.001
  Shock at presentation                                     97 (21.3)                59 (60.8)           5.75 (3.61-9.15)    \<0.001
  Neutropenia at presentation                                25 (5.5)                20 (20.6)           4.48 (2.37-8.46)    \<0.001
  Healthcare-associated infection                           243 (53.3)               70 (72.2)           2.27 (1.41-3.68)     0.001
  Polymicrobial infection                                   57 (12.5)                24 (24.7)           2.30 (1.34-3.94)     0.002
  Antimicrobial resistance                                                                                                       
    non-susceptible to CIP                                   32 (7.0)                 9 (9.3)            1.36 (0.63-2.94)     0.440
    non-susceptible to ESC                                   29 (6.4)                 8 (8.2)            1.32 (0.59-2.99)     0.499
  Inappropriate empirical antimicrobial therapy              27 (5.9)                13 (13.4)           2.46 (1.22-4.96)     0.010
  Inappropriate definitive antimicrobial therapy^b^        12/446 (2.7)              2/55 (3.6)          1.37 (0.30-6.26)     0.659

Data indicate no. (%) of patients.

WIC, weighted index of co-morbidity; CIP, ciprofloxacin; ESC, extended-spectrum cephalosporin; OR, odds ratio; CI, confidence interval.

^a^ Others were one appendicitis, one pericarditis and two periodontitis.

^b^ 52 patients were excluded from the analysis (15 patients were transferred to other hospitals and 37 died before the culture results were available).

From the multivariate logistic regression analysis, significant risk factors for 30-day mortality were high (≥3) Charlson's weighted index of co-morbidity (adjust odds ratio \[aOR\], 3.23; 95% CI, 1.88-5.57), high (≥4) Pitt bacteremia score (aOR, 8.43; 95% CI, 4.70-15.11), neutropenia (aOR, 2.60; 95% CI, 1.24-5.48), polymicrobial infection (aOR, 2.36; 95% CI, 1.21-4.60) and inappropriate empirical antimicrobial therapy (aOR, 2.43; 95% CI, 1.07-5.52). Liver abscess (aOR, 0.17; 95% CI, 0.05-0.58) and pancreatobiliary tract infection (aOR, 0.42; 95% CI, 0.23-0.79) were found to be protective factors (Table [4](#T4){ref-type="table"}). HCA infection was not an independent risk factor for mortality in multivariate analysis (aOR, 1.27; 95% CI, 0.70-2.30).

###### 

**Significant risk factors for 30-day mortality among community-onset*Klebsiella pneumoniae*bloodstream infection in multivariate analysis**

                                                   **No. of survivors (n = 456)**   **No. of non-survivors (n = 97)**  **Adjusted OR (95% CI)**    ***p***
  ----------------------------------------------- -------------------------------- ----------------------------------- -------------------------- ---------
  Charlson\'s WIC (≥3)                                       135 (29.6)                         53 (54.6)              3.23 (1.88-5.57)            \<0.001
  Pitt bacteremia score (≥4)                                 46 (10.1)                          46 (47.4)              8.43 (4.70-15.11)           \<0.001
  Neutropenia                                                 25 (5.5)                          20 (20.6)              2.60 (1.24-5.48)             0.012
  Polymicrobial infection                                    57 (12.5)                          24 (24.7)              2.36 (1.21-4.60)             0.012
  Pancreatobiliary infection                                 163 (35.7)                         21 (21.6)              0.42 (0.23-0.79)             0.006
  Liver abscess                                              105 (23.0)                          3 (3.1)               0.17 (0.05-0.58)             0.038
  Inappropriate empirical antimicrobial therapy               27 (5.9)                          13 (13.4)              2.43 (1.07-5.52)             0.035

Data indicate no. (%) of patients.

WIC, weighted index of co-morbidity; OR, odds ratio; CI, confidence interval.

Discussion
==========

In a previous study, we demonstrated that nosocomial *Kp*BSI was different from CA- *Kp*BSI \[[@B18]\]. However, the healthcare system has changed dramatically and this simple dichotomy is no longer appropriate for *Kp*BSI in the current clinical setting. In this study we showed that HCA-*Kp*BSI accounted for over 50% of community-onset *Kp*BSI and HCA-*Kp*BSI had different clinical characteristics from CA-*Kp*BSI in terms of underlying disease, infection focus, antimicrobial susceptibility and treatment outcome. To our knowledge, this is the largest multicenter study comparing the clinical characteristics of HCA-*Kp*BSI and CA-*Kp*BSI \[[@B11],[@B12]\].

Cancer was the most common associated condition in HCA-*Kp*BSI. In contrast, diabetes mellitus was the most common associated condition in CA-*Kp*BSI. The distribution of underlying disease in HCA-*Kp*BSI was similar to that in nosocomial *Kp*BSI, except for the frequency of chronic liver disease. While we found previously that the frequency of this disease did not differ between CA-*Kp*BSI and nosocomial *Kp*BSI \[[@B18]\], it was more common in HCA-*Kp*BSI than in CA-*Kp*BSI (27% vs*.* 16%; *p* = 0.003) in the present study. The latter finding is similar to that of a study performed in Taiwan, although in the Taiwanese study the difference was not statistically significant (liver cirrhosis in HCA-*Kp*BSI \[14.0%\] vs. CA- *Kp*BSI \[10.6%\]; *p* = 0.339) \[[@B12]\].

The primary site of infection was identified in 87% of community-onset *Kp*BSI. The most common source was the pancreatobiliary tract (33%), followed by liver abscess (20%). Liver abscess was more frequent in CA-*Kp*BSI than in HCA-*Kp*BSI. Compared to nosocomial *Kp*BSI, in which liver abscess was very rare (0% to 2%) \[[@B11],[@B14],[@B18]\], HCA-*Kp*BSI was quite frequently associated with liver abscess (13%). Peritonitis was fairly frequent (\>10%), more so in HCA-*Kp*BSI than in CA-*Kp*BSI in our analysis; in contrast Wu *et al*. found only a few (\<5%) of intra-abdominal infection and no difference in frequency between HCA-*Kp*BSI and CA-*Kp*BSI \[[@B12]\]. Our higher frequency of peritonitis may be due to the prevalence of chronic liver disease caused by hepatitis B or C virus in Korea, which increases the occurrence of spontaneous bacterial peritonitis \[[@B27],[@B28]\].

More of the HCA-*Kp*BSI isolates than of the CA-*Kp*BSI isolates were resistant to antimicrobial agents. Over 10% of the former were not susceptible to ciprofloxacin and 9% were not susceptible to one of the extended-spectrum cephalosporin. Although frequent antimicrobial resistance could affect the inadequacy of the initial choice of antimicrobial agent, there was no difference in rate of inappropriate empirical antimicrobial therapy between the HCA-*Kp*BSI and the CA-*Kp*BSI (6% vs. 8%; *p* = 0.266). This result could have arisen because in cases of healthcare-associated infection clinicians may have taken into account frequencies of antimicrobial resistance when selecting the initial antibiotic. Actually, fewer HCA-*Kp*BSI than CA-*Kp*BSI (6% vs. 10%; *p* = 0.088) were started on quinolones while more were started on piperacillin-tazobactam (Table [1](#T1){ref-type="table"}).

Regarding empirical treatment, the proportion of patients treated inappropriately (7.2% of total patients) was much lower than was observed in other studies, which showed that over 20% of patients were treated inappropriately \[[@B9],[@B29],[@B30]\]. This discrepancy might have been the result of differences in the definition of 'appropriate empirical treatment', because the definition we used was less strict than those in other studies \[[@B31]-[@B33]\]. In addition, broad-spectrum antimicrobial agents, such as 3^rd^ generation cephalosporins or carbapenems, were frequently used empirically in our study (84.6% in CA infection, 74.7% in HCA infection). Considering that only 3.3% of organisms in CA infection and 9.3% of organisms in HCA infection were non-susceptible to extended-spectrum cephalosporins, the use of broad-spectrum antimicrobial agents also might have influenced the lower proportion of patients with treated inappropriately. However, other East Asian studies of *K. pneumoniae* bacteremia also demonstrated a similar proportion of patients treated with inappropriate empirical therapy \[[@B12],[@B14],[@B18]\].

There was a significant difference of 30-day mortality rate between HCA-*Kp*BSI and CA-*Kp*BSI in this study (22% vs. 11%; *p* = 0.001). High Charlson's weighted index of co-morbidity (≥3), high Pitt bacteremia score (≥4), neutropenia, polymicrobial infection and inappropriate empirical antimicrobial therapy were found to be independent risk factors for mortality. However, HCA infection itself was not a significant risk factor for 30-day mortality in multivariate analysis. This finding is consistent with the recent report from Taiwan and a bloodstream infection study dealing with gram-negative bacteria \[[@B9],[@B12]\]. There are several explanations for this result. First, in our study, underlying disease and acute illness, which are classical risk factors for outcome of infectious disease, may have been so severe as to have attenuated the effect of HCA infection on mortality \[[@B23],[@B24],[@B34]\]. Second, whether the infection focus was removable, and was or was not removed, may have affected mortality more than whether the infection was HCA or not \[[@B35]\]. Liver abscess and pancreatobiliary infection can be classified as infections with removable foci, as opposed to pneumonia or primary bacteremia. In our study, percutaneous or internal drainage was performed in cases of liver abscess and obstructive pancreatobiliary infection, and these kinds of infection were found to be independent protective factors for mortality, as in the previous studies \[[@B11],[@B14],[@B18]\]. Third, as indicated by Friedman *et al*., the definition of HCA infection which we used in this study may have been excessively broad since the definition was based on the U.S. medical system \[[@B1]\]. Unlike the U.S., South Korea has started a national health insurance system in 1977 and extended it nationwide in 1982. Consequently, there is a tendency for more people to access the medical system and be classified as HCA infection in Korea. Such national differences in healthcare systems could complicate the unambiguous identification of patients with HCA infections so as to be able to evaluate the actual effect of HCA infection on mortality. Therefore we need further studies using a more accurate and consistent definition of HCA infection that accords better with variations in clinical practice.

Our study had several limitations. First, there was a potential bias because it was performed retrospectively. Second, it was conducted in tertiary-care and university-affiliated hospitals and there was a large proportion of cancer patients in both the CA-*Kp*BSI and HCA-*Kp*BSI groups. Hence, we cannot extrapolate our result to community-based institutions. Third, we did not evaluate the 'attributable' mortality due to *Kp*BSI, so that some of the deaths in our study may not have been related to *Kp*BSI. However, efforts to designate outcomes as 'attributable' to infection are often subjective and inconsistent. We therefore employed an unambiguous definition, namely 30-day mortality rate, for evaluating treatment outcomes. Fourth, because we did not review the patients' previous exposure to antimicrobial agents, we could not determine the influence of that factor on the acquiring resistant organisms and treatment outcome. Additionally, we did not collect data on the variation of antimicrobial therapy, such as duration or dosage; therefore, we could not take into account these issues, which could affect the analysis of risk factors for mortality. However, upon examining the mortality rate in other studies, our data are comparable; therefore, the regimen and duration of therapy we used were also likely to be similar to others \[[@B12],[@B14]\].

What clinicians actually want to know is that HCA infection needs a specific work-up process or treatment. Accordingly, our study can provide useful information. First, we could see the difference of infection focus according to the epidemiological category more clearly by separating HCA infection and CA infection in comparison to our previous report \[[@B18]\]. Peritonitis is more commonly associated with HCA infection than with CA infection in the present study, while the frequency of peritonitis in CA infection was relatively high (20.4%) and was not different from that observed in nosocomial infection in the previous study \[[@B18]\]. However, when we classified more precisely we could see that peritonitis occurred in much lower frequency in true CA infection. In addition, we could identify the infection focus of all but 8.8% of the patients with true CA infection (in previously defined CA infection, 25.7% patients were unidentified for infection focus) \[[@B18]\]. Second, comparing the resistance rate to antimicrobial agents in HCA infection with CA infection can help clinicians choose an initial antimicrobial agent in treating patients of each subset, which means not only should we consider broad-spectrum antimicrobial agents in HCA infection but also that we may not need to start broad-spectrum antimicrobial agents, such as extended-spectrum cephalosporins or carbapenems, in CA infection. Based on our data, quinolone can be a drug of choice in treating true CA-*Kp*BSI. Finally, even though we showed many differences between HCA infection and CA infection, we did not find HCA infection to be an independent risk factor for mortality in *Kp*BSI, which confirmed that the already known risk factors for mortality (severity of underlying disease, inadequate empirical therapy and severity of acute illness) are more important predictors of mortality in *Kp*BSI \[[@B12],[@B14]\].

Conclusion
==========

HCA-*Kp*BSI represented over half of community-onset *Kp*BSI and had different characteristics from CA-*Kp*BSI. In HCA-*Kp*BSI, underlying diseases were more severe, primary bacteremia and peritonitis were more common and resistance to antimicrobials was more frequent than in CA-*Kp*BSI. HCA-*Kp*BSI had higher 30-day mortality than CA-*Kp*BSI, but HCA infection was not an independent risk factor for 30-day mortality. In present-day clinical circumstances, HCA-*Kp*BSI should be identified as a distinctive category and be approached in a different way from CA-*Kp*BSI.
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